Strategic Forecast for the HERG Screening Industry: Market Outlook 2025-2034

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts

HERG Screening Market Size Growth Forecast: What to Expect by 2025?
The market size for HERG screening has seen swift expansion in the past few years. The market is projected to escalate from $1.62 billion in 2024 to $1.84 billion in 2025, marking a compound annual growth rate (CAGR) of 13.9%. Its growth in the historic period was fueled by factors such as heightened activities around drug development, regulatory obligations, a growing understanding of cardiac safety, and an increasing prevalence of cardiac conditions.

How Will the HERG Screening Market Size Evolve and Grow by 2029?
Expectations are high for the HERG screening market as it is projected to experience significant growth in the coming years. By 2029, this market is anticipated to reach $2.9 billion, with an annual compound growth rate (CAGR) of 12.0%. Various factors such as the expansion of personalized medicine, escalation of outsourced drug development activities, emerging markets and research, as well as an emphasis on non-cardiac safety assessments, contribute to this projected growth within the forecast period. The period is also expected to witness key trends like the development of advanced in vitro models, integration of genomic and proteomic data, enhancements in computational methodologies, focus on the security of pediatric drugs, along with collaborations for data sharing and standardization.

View the full report here:
https://www.thebusinessresearchcompany.com/report/herg-screening-global-market-report

What Drivers Are Propelling the Growth of HERG Screening Market Forward?
The increase in heart disease patients is anticipated to drive the expansion of the HERG screening market. Heart diseases, also known as cardiovascular disorders, encompass a variety of conditions affecting the heart and blood vessels. These ailments can alter the heart's normal function, potentially leading to severe health issues. Unhealthy lifestyles, an aging society, genetic predisposition, diabetes, and metabolic syndrome are all contributing factors to these disorders. HERG screening is instrumental in identifying potential drug candidates, preventing severe cardiovascular events liable to cause deadly heart arrhythmias, especially torsade de pointes (TdP), while enhancing patient outcomes. For instance, in May 2023, the Centers for Disease Control and Prevention, a US national public health agency, reported that 1 in 20 adults over 20 suffer from cardiovascular diseases. This represented 695,000 cardiovascular disease patients and 375,476 deaths from these diseases. Additionally, in March 2022, the Office for National Statistics, a UK government department, revealed that heart attack deaths stood at 20,061, marking an increase from the previous year. Consequently, the surge in heart disease patients propels the HERG screening market's growth.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=14392&type=smp

Which Emerging Trends Are Transforming the HERG Screening Market in 2025?
Leaders in the HERG screening market such as prominent companies are focusing on creating and offering new state-of-the-art solutions. These include services that offer GLP-certified HERG screening alternatives designed to improve the assessment of cardiac safety during drug formulation. This kind of service revolves around fulfilling best laboratory procedures in screening the human ether-à-go-go related gene (hERG) via the traditional whole-cell patch-clamp method. Notably, this service operates under the guidelines set by the regulators, particularly ICH S7A and ICH S7B, which are mandated for safety pharmacology studies during the development of drugs. For illustration, Metrion Biosciences Ltd., a pharmaceutical entity headquartered in the UK, introduced the GLP-certified hERG screening service in August 2023. The aim of rolling out this service centered around augmenting Metrion's contribution to the development of small-molecule therapeutics and ing the company's already existing cardiac safety services. Moreover, the service uses the conventional whole-cell patch-clamp method to foresee potential cardiac risks before the commencement of Phase 1 clinical examinations in humans, offering regulatory counsel for safety pharmacology inquiries in drug development, and supplying high-quality biology solutions for ion channel targets to customers.

What Are the Key Segments in the HERG Screening Market?
The HERG screening market covered in this report is segmented -

1) By Type: Gene KCNH2, Mutant KCNH2
2) By Ion Channel: Voltage-Gated, Ligand Gated
3) By Applications: Antiarrhythmic, Antipsychotic, Antibiotics, Other Applications

Subsegmeents:
1) By Gene KCNH2: Wild-Type KCNH2, Recombinant KCNH2
2) By Mutant KCNH2: Mutations: Missense Mutations, Nonsense Mutations, Frameshift Mutations

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=14392&type=smp

Who Are the Key Players Shaping the HERG Screening Market's Competitive Landscape?
Major companies operating in the HERG screening market are Eurofins-Cerep SA., Aviva Biosciences Inc., AstraZeneca Public Limited Company, Merck KGaA, Charles River Laboratories Inc., Abcam Public Limited Company, Molecular Devices LLC, Caliper Life Sciences Inc., Crprotex Limited, ChanTest Corporation, Creative bioarray Inc., Cellular Dynamics International Inc., Nanion Technologies, Essen Bioscience, ABR-Affinity BioReagents Inc., ACEA Biosciences Inc., Metrion biosciences Inc., Aurora Biomed Inc., Aureus Sciences, RedShift BioAnalytics, B'SYS GmbH, Cambridge Bioscience Ltd., Sophion Bioscience Inc., Fluxion Biosciences Inc., ChemAxon Ltd.

What Geographic Markets Are Powering Growth in the HERG Screening Market?
North America was the largest region in the HERG screening market in 2024. Asia-Pacific is expected to be the fastest growing region in the forecast period. The regions covered in the HERG screening market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=14392

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.